ClinicalTrials.gg
RecruitingNCT07309250GITTPopUpdated Nov 13, 2026

A Study on Gastrointestinal Transit Time at the Population Level

An observational study in Gastrointestinal Transit Time, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by KU Leuven · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 13, 2026Now RecruitingStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
932
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to investigate the baseline of gastrointestinal transit time (GITT) and explore its relationship with other health indicators in 932 healthy adult volunteers.

The main questions it aims to answer are:

What are the population-level baseline values for GITT using the blue dye method? How is GITT associated with key physiological parameters including blood metabolic markers, life style, and stool characteristics?

Participants will:

Consume a standardized blue dye muffin after overnight fasting at the research center; Offer a finger prock blood samples for metabolic profiling; Offer a saliva sample for whole exome sequencing analysis; Collect stool samples for moisture measurement; Complete detailed questionnaires on diet, lifestyle, and bowel habits; Record the time of first blue stool appearance to determine GITT.

Read the detailed description

This explorative study is designed as a cross-sectional investigation aimed at establishing population-level reference values for gastrointestinal transit time (GITT). Adult participants from the general population will undergo GITT measurement using the blue-dye method. This muffin contains blue colorant that cannot be absorbed; after ingestion, it passes through the entire gastrointestinal tract and is eventually excreted in feces. Following a two-day lifestyle standardization period (including dietary and activity guidance) to minimize potential confounding effects on gastrointestinal motility, participants will attend a clinical visit where they will ingest a blue muffin. GITT will be determined by measuring both the time interval between ingestion of the blue muffin and the first appearance of blue-colored stool, and the duration from its first appearance to its complete disappearance.

The blue muffin method has been well-established in previous research for GITT assessment. Building upon the methodology developed by Berry et al., we will introduce stricter pre-test condition controls (includes dietary advice and lifestyle recommendations) and optimized the blue muffin formulation. These improvements allow for reliable measurement with a single muffin administration, which has been evaluated through KU Leuven Health Pass in a large sample size(S-70168).

To investigate potential determinants and correlates of GITT, we will collect biochemical parameters, fecal moisture, and resting metabolic rate. We will collect saliva samples for WGS to identify key genetic variants associated with GITT and use these findings to develop a genetic risk score. Additionally, participants will complete 24-h diet record and health questionnaires assessing bowel movement, physical activity habits, stress levels, sleep quality and hydration condition for subsequent correlation analyses.

02

Conditions studied

  • Gastrointestinal Transit Time

Keywords

  • Gastrointestinal motility
  • Baseline study
  • Reference value
03

In context

Lead sponsor

KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers from the Flanders region who volunteered to participate in the research

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-65 years old
  2. 18.5 kg/m² ≤ ≤ 25 kg/m² or BMI ≥ 30 kg/m² (people with normal weight or obesity)
  3. Provision of to participate.

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal conditions which may affect nutrient absorption or gastric emptying, including coeliac disease, Crohn's disease, previous resection of the small intestine other than bariatric surgery, gastroparesis;
  2. Using medications which effect gastric motility (e.g., domperidone, erythromycin, metoclopramide, prucalopride, opiates, loperamide, …)
  3. The ingredients of blue muffins include gluten, nuts, baking powder, sugar, vanilla extract and sunflower oil. Participants with allergies to these ingredients;
  4. Current diagnosis of cancer;
  5. Advanced organ failure, including chronic kidney disease Stage 5, liver cirrhosis B or C, intestinal failure, heart failure stage D, or stage 4;
  6. Immobility;
  7. Neuromuscular degenerative conditions associated with muscular atrophy, such as myasthenia gravis, muscular dystrophies, fibromyalgia, or multiple Sclerosis;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
932 participants (estimated)
Target follow-up
5 Days
Patient registry
Yes

Groups and cohorts

  • Adult participants

    Healthy adult participants without serious gastrointestinal diseases

    Other: Diet

Interventions

  • OtherDiet

    Participants will consume a regular muffin containing blue dye

06

What researchers measure

Primary outcomes

  1. Gastrointestinal transit time

    Calculate the transit time by the recorded muffin consuming time, first blue stool appearance time and last blue stool appearance time

    Time frame: From enrollment to the end of study at 2 weeks

Secondary outcomes

  1. Height (cm)

    Measured using a height meter, in centimeters.

    Time frame: baseline

  2. Weight (kg)

    Measuring using a scale, in kg.

    Time frame: baseline

  3. BMI

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: baseline

  4. Blood glucose (mmol/L)

    Measure blood glucose by CardioChek Plus in mmol/L

    Time frame: baseline

  5. Fat mass (kg)

    Using Bodystat quadscan 4000 to measure fat mass (kg)

    Time frame: baseline

  6. Lean body mass(kg)

    Using Bodystat quadscan 4000 to measure lean body mass (kg)

    Time frame: baseline

  7. Fat percentage (%)

    Using Bodystat quadscan 4000 to measure fat%

    Time frame: baseline

  8. Total cholesterol (mmol/L)

    Measuring by Mission cholesterol Meter in mmol/L

    Time frame: baseline

  9. HDL-C (mmol/L)

    Measuring by Mission cholesterol Meter in mmol/L

    Time frame: baseline

  10. LDL-C (mmol/L)

    Measuring by Mission cholesterol Meter in mmol/L

    Time frame: baseline

  11. Triglyceride (mmol/L)

    Measuring by Mission Cholesterol Meter in mmol/L

    Time frame: baseline

  12. Food record

    Participants record their 24-h diets through smartphone application

    Time frame: 2 days after study

  13. Stool form

    Stool form will be evaluated by Bristol Stool Form Scale, the score is from 1 to 7, with values closer to the middle indicating more ideal stool shape.

    Time frame: baseline

  14. Hydration status

    Hydration status will be rated from 1 to 8 by Urine color chart, with higher numbers indicating that the body needs more water.

    Time frame: baseline

  15. Perceived level of stress

    The10-item Perceived Stress will be used to measures an individual's perceived level of stress over the past month. The total score ranges from 0 to 40. A higher score indicates a greater perceived level of stress.

    Time frame: baseline

  16. Sleep quality

    Pittsburgh Sleep Quality Index will be used to assess subjective sleep quality over the past month. The total score ranges from 0 to 21. A higher score indicates poorer sleep quality.

    Time frame: baseline

  17. Activity level

    The Baecke Physical Activity Questionnaire will be used to assess daily habitual physical activity, with a particular focus on work-related and exercise-related activities. It does not produce a single total score, but rather scores on three dimensions, each typically ranging from 1 to 5. On each dimension, a higher score indicates a higher level of physical activity in that area. Therefore, for assessing activity levels, a higher score is generally better.

    Time frame: baseline

  18. Whole genome sequencing (WGS)

    The genetic risk score will be calculated by summing the number of GITT-associated alleles carried by each participant, weighted by their estimated effect sizes. As the number and weights of the included variants will be determined during the analysis, the score does not have a predefined numerical range. The score will be standardized to a mean of 0 and a standard deviation of 1. A higher score will indicate a stronger genetic predisposition to the GITT phenotype of interest; it does not necessarily represent a better or worse health outcome.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • Department of Chronic Diseases and Metabolism
    Leuven, Flemish Brabant 3000, Belgium
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 30, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
Department of Chronic Diseases and Metabolism is now Recruiting
Oct 6, 2026
Documents
Secondary outcomes
1 added
What changed in the outcomes
  • AddedWhole genome sequencing (WGS)Time frame: baseline
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedWhole genome sequencing (WGS)Time frame: baseline
    + 2 other changes: verification date and description
  2. Oct 6, 2026
    Not yet recruiting→Recruiting
    Department of Chronic Diseases and Metabolism is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07309250
Lead sponsor
KU Leuven
Responsible party
Christophe Matthys (Professor, KU Leuven) — Principal investigator
First posted
Dec 30, 2025
Start date
Dec 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Christophe Matthys
Contact
christophe.matthys@uzleuven.be
+32 016342655
Wei Li
Contact
wei.li2@kuleuven.be
+32 016344539

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion